Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
Authors:
Open Access
- 15 April 2022
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (9) , 1201-1217
Abstract
The clinical presentation of Parkinson’s disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently remains uncertain from a clinical point of view. Various tissue- and fluid-based biomarkers are currently being investigated to improve the description of PD. From a clinician's perspective, signatures from blood that are relatively easy to obtain would have great potential for use in clinical practice if they fulfill the necessary requirements as PD biomarker. In this review article, we summarize the knowledge on blood-based PD biomarkers and present both a researcher’s and a clinician’s perspective on recent developments and potential future applications.Keywords
Funding Information
- Universitätsklinikum der Ruhr-Universität Bochum
This publication has 160 references indexed in Scilit:
- Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in SerumPLOS ONE, 2012
- CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s DiseaseJournal of Neuroimmune Pharmacology, 2012
- Parkinson Subtypes Progress Differently in Clinical Course and Imaging PatternPLOS ONE, 2012
- CD4+T Cells: Differentiation and FunctionsJournal of Immunology Research, 2012
- -Synuclein in Parkinson's DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeuticsJournal of Neural Transmission, 2011
- The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson's DiseasePsychosomatics, 2010
- SNCA Variant Associated With Parkinson Disease and Plasma α-Synuclein LevelArchives of Neurology, 2010
- Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive DeclineThe Journal of Neuroscience, 2010
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001